bay2433334
Small moleculeexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Jan 15, 2020 (NCT04218266)
Timeline
Indications
Mechanism of action
- Coagulation factor XIINHIBITOR
F11 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05686070 | Phase 3 | Jan 26, 2023 | Bayer |
| NCT05643573 | Phase 3 | Dec 5, 2022 | Bayer |
| NCT05419635 | Phase 1 | Jun 14, 2022 | Bayer |
| NCT04692181 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | Synthetic Biologics, Washington University in St. Louis |
| NCT04304534 | Phase 2 | Sep 1, 2020 | Bayer |
| NCT04304508 | Phase 2 | Sep 1, 2020 | Bayer |
| NCT04510987 | Phase 1 | Aug 12, 2020 | Bayer |
| NCT04218266 | Phase 2 | Jan 15, 2020 | Bayer |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 7 | 7 | 3 | 2020 |
| Synthetic Biologics | For profit | 1 | 1 | 1 | 2020 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1